Skip to main content

Table 4 Comparison of quality of life scores between two groups after treatment

From: Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

 

ECF group

TCF group

 

Functioning scores 1

Mean (SD) score

Mean (SD) score

P3

Physical functioning

69.4 (14.9)

68.3 (19.1)

0.81

Role functioning

69.1 (16.7)

70.8 (21.2)

0.71

Emotional functioning

63.9 (12.5)

64.6 (13.5)

0.82

Cognitive functioning

83. 2 (11.4)

78.1 (13.1)

0.08

Social functioning

65. 8(15.6)

73.7 (15.5)

0.03

Global quality of life

57.6 (15.1)

54.8 (16.3)

0.46

Symptom scores 2

   

Fatigue

42.5 (12.7)

44.9 (16.7)

0.48

Nausea and vomiting

19.3 (16.7)

32.4 (26.1)

0.01

Pain

32.8 (17.1)

41.4 (22.6)

0.08

Dyspnoea

7.6 (16.3)

11.1 (21.1)

0.13

Sleep difficulties

25.5 (21.4)

29.4 (22.2)

0.45

Appetite loss

34.4 (24.9)

40.8 (27.7)

0.31

Constipation

13.2 (21.2)

15.7 (25.8)

0.65

Diarrhoea

13.6 (19.9)

9.5 (17.0)

0.35

Financial difficulties

61.4 (25.7)

56.0 (24.8)

0.37

  1. 1 Higher scores show better functioning and global quality of life.
  2. 2 Higher scores indicate greater symptoms.
  3. 3 P values derived from independent samples t-tests.
  4. SD = Standard deviation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us